OPM MEG Brain Activity Mapping
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new sensor that measures the brain's magnetic fields to pinpoint brain activity more accurately. Participants will use both the traditional MEG device and the new OPM sensor (Optically Pumped Magnetometer Magnetoencephalography), which is worn on a cap. The trial includes tasks involving touch, visual, auditory, or language stimuli to measure brain responses. Ideal candidates are healthy individuals who have already undergone a specific MRI scan and are free from metal in their body. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research in brain activity measurement technology.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that this OPM MEG is safe for measuring brain activity?
Research has shown that the new OPM MEG technology is safe and easy to tolerate. Studies have found that OPM MEG provides better data quality than older methods without requiring extreme conditions like heating, making it more comfortable and easier to use.
The sensors in OPM MEG operate at room temperature and are placed in a cap worn on the head, which is non-invasive. This means they do not enter the body. No significant unexpected medical problems have been reported in these studies related to OPM MEG use. Although this technology is still undergoing testing to ensure safety and effectiveness, current findings suggest it is promising in terms of safety.12345Why are researchers excited about this trial?
Researchers are excited about the OPM MEG Brain Activity Mapping because it uses a new kind of magnetoencephalography technology that may offer more detailed brain imaging. Unlike standard SQUID MEG systems, which rely on supercooled detectors, OPM MEG uses optically pumped magnetometers that work at room temperature. This setup could make the system more portable and comfortable for patients, potentially leading to more widespread use in studying and diagnosing neurological conditions. By improving the resolution and comfort of brain scans, researchers hope to gain better insights into brain activity.
What evidence suggests that the OPM MEG is effective for brain activity mapping?
Research shows that the new OPM-MEG technology, which participants in this trial will experience, could significantly enhance the study of brain activity. Studies have found that OPM-MEG can detect brain signals in areas difficult to reach with older methods, such as the cerebellum. This technology also offers better sensitivity and spatial resolution, capturing clearer and more detailed information about brain function. Researchers are exploring its potential to identify problems in conditions like schizophrenia and epilepsy, providing insights previously unattainable. Overall, OPM-MEG may offer a more detailed understanding of brain function compared to current methods.24678
Who Is on the Research Team?
Allison C Nugent, Ph.D.
Principal Investigator
National Institute of Mental Health (NIMH)
Are You a Good Fit for This Trial?
Healthy adults aged 18-65 who've had an MRI scan under a specific protocol can join this study. They should be in good health, able to follow the study's procedures, and available for its duration. People with metal in their body that affects MEG recordings cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Testing
Participants undergo testing with both the traditional MEG instrument and the OPM array, including various sensory tasks and nerve stimulation.
Optional Follow-up
Additional optional scans may be offered to participants for further testing and data collection.
What Are the Treatments Tested in This Trial?
Interventions
- OPM MEG
- SQUID MEG
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Institute of Mental Health (NIMH)
Lead Sponsor